IXC 2.86% 7.2¢ invex therapeutics ltd

Ann: Appendix 4E and Annual Report, page-39

  1. 395 Posts.
    lightbulb Created with Sketch. 48
    This is a great find @JabraD. They have demonstrated in sample of 66 pts with IIH (with a control group of 25 healthy females) that cognition is impaired in IIH (e.g., sustained attention and executive function) and that these deficits improve over a 12-month period with a reduction intracranial pressure. We also have to note that the control group is fairly small (n=25) and that the statistical power comes from the lowest group size. So, with a greater sample, they could have found deficits across multiple cognitive domains. Yes, there is a conflict of interest here with Prof. Sinclair, but the results make sense - of course these deficits are going to affect visual performance. I wonder if cognition will feature at all in their secondary or exploratory outcomes in their Phase 3 trial design.
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
7.2¢
Change
0.002(2.86%)
Mkt cap ! $5.411M
Open High Low Value Volume
7.2¢ 7.2¢ 7.2¢ $1.701K 23.62K

Buyers (Bids)

No. Vol. Price($)
2 76375 7.2¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 5000 1
View Market Depth
Last trade - 15.42pm 13/09/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.